Ashley Hall - 09 Dec 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Role: Chief Development Officer
Signature: /s/ Jennifer P. Lam, Attorney-in-Fact
Issuer symbol: OKUR
Transactions as of: 09 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 13 Dec 2022, 17:11:48 UTC
Previous filing: 15 Nov 2021
Next filing: 29 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	RPHM	Common Stock						35,600	09 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPHM	Stock option (right to buy)	Award	$0	+125,000		$0.000000	125,000	09 Dec 2022	Common Stock	125,000	$1.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022.
F2	The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.